OSR | 10-Q: FY2025 Q2 Revenue: USD 1.136 M

Revenue: As of FY2025 Q2, the actual value is USD 1.136 M.

EPS: As of FY2025 Q2, the actual value is USD -0.69.

Segment Revenue

• Net Sales: $1,135,517 for the three months ended June 30, 2025, compared to $881,829 for the same period in 2024, representing a 29% increase.
• Net Sales: $1,896,789 for the six months ended June 30, 2025, compared to $1,792,054 for the same period in 2024, representing a 6% increase.

Operational Metrics

• Gross Profit: $32,782 for the three months ended June 30, 2025, compared to $232,321 for the same period in 2024, representing an 86% decrease.
• Gross Profit: $201,468 for the six months ended June 30, 2025, compared to $472,122 for the same period in 2024, representing a 57% decrease.
• Operating Loss: -$5,229,177 for the three months ended June 30, 2025, compared to -$3,210,108 for the same period in 2024, representing a 63% increase.
• Operating Loss: -$8,147,004 for the six months ended June 30, 2025, compared to -$6,512,636 for the same period in 2024, representing a 25% increase.
• Loss Before Income Taxes: -$5,225,198 for the three months ended June 30, 2025, compared to -$3,251,115 for the same period in 2024, representing a 61% increase.
• Loss Before Income Taxes: -$16,618,012 for the six months ended June 30, 2025, compared to -$6,606,477 for the same period in 2024, representing a 152% increase.

Cash Flow

• Net Cash Used in Operating Activities: -$546,678 for the six months ended June 30, 2025, compared to -$981,991 for the same period in 2024.
• Net Cash Provided by Investing Activities: $657,167 for the six months ended June 30, 2025, compared to $446,192 for the same period in 2024.
• Net Cash Provided by Financing Activities: $1,040,863 for the six months ended June 30, 2025, compared to $524,848 for the same period in 2024.

Unique Metrics

• Accumulated Deficit: -$30,175,318 as of June 30, 2025, compared to -$19,173,063 as of December 31, 2024.
• Debt Ratio: 3.2% as of June 30, 2025, compared to 1.4% as of December 31, 2024.

Future Outlook and Strategy

Core Business Focus

• Tokenization Initiative: OSRH announced a strategic roadmap for tokenizing its equity in partnership with BCM Europe AG, aiming to leverage blockchain-based finance to enhance capital raising opportunities and increase liquidity.
• Acquisition of Woori IO: OSRH signed a term sheet to acquire Woori IO, a leader in noninvasive glucose monitoring technology, to strengthen its presence in the healthcare and medical technology sectors.

Non-Core Business

• Equity Line of Credit (ELOC): OSRH entered into an ELOC agreement providing up to $80 million in potential capital, with $741,937 raised through June 30, 2025.

Priority

• R&D Expenses: OSRH expects to incur R&D expenses of $2.5 million to $3.0 million per quarter beginning in the second half of 2025, potentially increasing to $5.0 million to $6.0 million per quarter.